Everolimus
From Wikipedia, the free encyclopedia
| Image:Everolimus.png | |
| Everolimus
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | L04AA18 |
| PubChem | 6442177 |
| Chemical data | |
| Formula | C53H83NO14 |
| Mol. weight | 958.224 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Everolimus (RAD-001) is a new mTOR inhibitor drug used as an immunosuppressant to prevent rejection of organ transplants. It, along with other mTOR inhibitors, is used as a cancer suppressing drug. It is related to Sirolimus (Rapamycin), and works in the same way.
Everolimus may have a role in heart transplantation as it has been shown to reduce chronic allograft vasculopathy in such transplants. It also may have a similar role to sirolimus in kidney and other transplants.
Eisen HJ, Tuzcu EM, Dorent R, et al: Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients. New England Journal of Medicine 2003; 349:847-858
It does not have FDA approval in the USA.
It is used in European countries. The contra-indication in the use of everolimus is a certain rise in cholesterol levels and therefore an increased cardio-vascular risk.
Everolimus is under investigation as an immunosuppressant to prevent rejection of Coronary stents.
